This first edition is published by Springer Nature Switzerland AG under the Springer imprint. The work is protected by international copyright law, with all rights reserved regarding translation, reprinting, and reproduction.
The publication carries ISBN 978-3-030-44461-7 (Print) and 978-3-030-44462-4 (eBook), and it includes a legal notice stating that while the content is believed to be accurate at the time of publication, the publisher and editors provide no express or implied warranty for any errors or omissions.
The introductory material highlights a significant clinical gap: as oncology therapies advance, more patients are living with cancer as a chronic condition, yet they often face significant and progressive functional disability that remains untreated.
The authors' primary intent is to provide a framework for impairment-driven cancer rehabilitation, addressing the "tremendous lack of knowledge" among clinicians regarding available services.
The book aims to fill the gap between increasing survival rates and the often-neglected "functional morbidity burden" caused by surgery, chemotherapy, and radiation. The intended audience includes rehabilitation specialists (physiatrists), oncologists, and members of the interdisciplinary care team—such as physical and occupational therapists—who require a portable resource to help maintain or restore function and improve quality of life for medically complex cancer survivors.
For the practicing physician, this guide offers a high-yield, organ-system-specific approach to identifying and managing the physical and cognitive impairments that affect nearly 40% of the population who will develop cancer in their lifetime. It provides clinical tools for prehabilitation, allowing doctors to optimize a patient's functional baseline before the stress of acute treatment, and offers specific management strategies for complex syndromes like radiation fibrosis, lymphedema, and postmastectomy pain. By integrating these rehabilitation principles, clinicians can move beyond treating the malignancy alone to actively preserving their patients' independence and long-term quality of life.
Comments: